[Retracted] Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer

Table 5

Multivariate logistic regression analysis of ORR.

Variables	HR	95% CI
Age (>50 years old vs ≤50 years old)	1.132	0.806~1.362	0.239
ECOG score (2 points vs. ≤1 point)	1.285	0.859~1.933	0.088
Number of treatment lines (second-line vs. third-line)	0.362	0.119~0.895	0.005
Chemotherapy drugs (capecitabine vs. others)	0.880	0.567~0.994	0.036
Hormone status (positive vs. negative)	0.925	0.445~1.369	0.167
Pathological type (invasive cancer vs. other)	1.125	0.859~1.492	0.265
Brain metastasis (yes vs. no)	1.425	1.138~2.502	0.007